Kathleen Mullane to Aged
This is a "connection" page, showing publications Kathleen Mullane has written about Aged.
Connection Strength
0.544
-
Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a two-arm, randomised, double-blind, phase 3 trial. Lancet Infect Dis. 2019 09; 19(9):1001-1012.
Score: 0.053
-
A Randomized, Placebo-controlled Trial of Fidaxomicin for Prophylaxis of Clostridium difficile-associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation. Clin Infect Dis. 2019 01 07; 68(2):196-203.
Score: 0.051
-
Isavuconazole for treatment of rare invasive fungal diseases. Mycoses. 2018 Aug; 61(8):518-533.
Score: 0.050
-
Surotomycin versus vancomycin for Clostridium difficile infection: Phase 2, randomized, controlled, double-blind, non-inferiority, multicentre trial. J Antimicrob Chemother. 2016 10; 71(10):2964-71.
Score: 0.043
-
Multicenter, randomized clinical trial to compare the safety and efficacy of LFF571 and vancomycin for Clostridium difficile infections. Antimicrob Agents Chemother. 2015 Mar; 59(3):1435-40.
Score: 0.039
-
Safety and immunogenicity of heat-treated zoster vaccine (ZVHT) in immunocompromised adults. J Infect Dis. 2013 Nov 01; 208(9):1375-85.
Score: 0.035
-
Renal impairment and clinical outcomes of Clostridium difficile infection in two randomized trials. Am J Nephrol. 2013; 38(1):1-11.
Score: 0.035
-
Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections. Clin Infect Dis. 2011 Sep; 53(5):440-7.
Score: 0.031
-
Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. JAMA. 2020 09 15; 324(11):1048-1057.
Score: 0.014
-
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. N Engl J Med. 2020 11 05; 383(19):1827-1837.
Score: 0.014
-
Misdiagnosis of Bordetella bronchiseptica Respiratory Infection as Bordetella pertussis by Multiplex Molecular Assay. Clin Infect Dis. 2018 11 28; 67(12):1919-1921.
Score: 0.013
-
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Oral Brincidofovir for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2019 02; 25(2):369-381.
Score: 0.013
-
Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2018 05 26; 391(10135):2116-2127.
Score: 0.012
-
Isavuconazole for treatment of invasive fungal diseases caused by more than one fungal species. Mycoses. 2018 Jul; 61(7):485-497.
Score: 0.012
-
Impact of unresolved neutropenia in patients with neutropenia and invasive aspergillosis: a post hoc analysis of the SECURE trial. J Antimicrob Chemother. 2018 03 01; 73(3):757-763.
Score: 0.012
-
Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation. N Engl J Med. 2017 12 21; 377(25):2433-2444.
Score: 0.012
-
Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease. J Antimicrob Chemother. 2017 Dec 01; 72(12):3406-3413.
Score: 0.012
-
The Impact of Recurrent Clostridium difficile Infection on Patients' Prevention Behaviors. Infect Control Hosp Epidemiol. 2017 11; 38(11):1351-1357.
Score: 0.012
-
Safety and Durability of RBX2660 (Microbiota Suspension) for Recurrent Clostridium difficile Infection: Results of the PUNCH CD Study. Clin Infect Dis. 2016 Mar 01; 62(5):596-602.
Score: 0.010
-
Correlation between Circulating Fungal Biomarkers and Clinical Outcome in Invasive Aspergillosis. PLoS One. 2015; 10(6):e0129022.
Score: 0.010
-
Histoplasmosis after solid organ transplant. Clin Infect Dis. 2013 Dec; 57(11):1542-9.
Score: 0.009
-
Resolution of Clostridium difficile-associated diarrhea in patients with cancer treated with fidaxomicin or vancomycin. J Clin Oncol. 2013 Jul 01; 31(19):2493-9.
Score: 0.009
-
Derivation and validation of a simple clinical bedside score (ATLAS) for Clostridium difficile infection which predicts response to therapy. BMC Infect Dis. 2013 Mar 25; 13:148.
Score: 0.009
-
Reduced acquisition and overgrowth of vancomycin-resistant enterococci and Candida species in patients treated with fidaxomicin versus vancomycin for Clostridium difficile infection. Clin Infect Dis. 2012 Aug; 55 Suppl 2:S121-6.
Score: 0.008
-
Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med. 2011 Feb 03; 364(5):422-31.
Score: 0.007
-
Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection. Antimicrob Agents Chemother. 2009 Jan; 53(1):223-8.
Score: 0.006
-
Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplant. 2007 Apr; 39(7):425-9.
Score: 0.006
-
Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother. 2006 Jan; 50(1):126-33.
Score: 0.005
-
Recombinant urokinase for restoration of patency in occluded central venous access devices. A double-blind, placebo-controlled trial. Thromb Haemost. 2004 Sep; 92(3):575-82.
Score: 0.005